Financials
Financial year 2025
Biopsy from Lennik, company number BE0686920346, closed financial year 2025 with a result of € 141,007 after tax. For that financial year Biopsy recorded a gross margin of € 204,844 and equity of € 20,460. Compared with financial year 2024, the result moved from € 171,885 to € 141,007. The company is profitable. The buffer shrank hard: equity is 79 % below last year. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on July 3, 2026.
€ 20,460
▼ 79% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 141,007
▼ 18% vs 2024
Profit after tax over the fiscal year.
€ 72,687
▼ 55% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 218,775 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 12,141
▼ 11% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 11,348
▲ 127% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,072
▼ 40% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 2,301
▲ 181% vs 2024
Wages, holiday pay and social contributions still to pay. No outstanding taxes.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 197,198 | € 239,276 | € 250,070 | € 204,844 | ▼ 18% |
| Profit after taxes | € 135,764 | € 163,441 | € 171,885 | € 141,007 | ▼ 18% |
| Equity | € 20,460 | € 20,460 | € 98,228 | € 20,460 | ▼ 79% |
| Total debts | € 120,053 | € 188,735 | € 103,392 | € 109,105 | ▲ 6% |
| Cash | € 99,514 | € 153,232 | € 160,284 | € 72,687 | ▼ 55% |
| Retained profit | € 1,860 | € 1,860 | € 79,628 | € 1,860 | ▼ 98% |
| Dividend | € 135,764 | € 163,441 | € 94,117 | € 218,775 | ▲ 132% |
| Balance sheet total | € 140,513 | € 209,195 | € 201,620 | € 129,565 | ▼ 36% |
Key figures of Biopsy, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Biopsy?
What happened at Biopsy in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 141,007 (▼ 18% vs 2024). Source: NBB ↗
- Liesbeth Seaux became a director. NBB
- New establishment in Lennik. KBO
- Jonas Rooseleer became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 135,764 profit in 2022 to € 141,007 profit in 2025.
Paid € 190,600 in corporate taxes since 2022.
Best year ever: 2024, with € 171,885 profit.
Paid out € 612,097 in dividends to the owners in total.
Management
Behind Biopsy are Jonas Rooseleer and Liesbeth Seaux.
Directors
According to the 2025 annual accounts
Jonas Rooseleer
Manager
since 2017
Liesbeth Seaux
Director
since 2021
Establishments
Establishment units
Physical locations of this company
Hunselstraat 97
1750 Lennik
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0686.920.346
- VAT number
- BE 0686.920.346
- Registered office
- Hunselstraat 97, 1750 Lennik
- Names & denominations
- Biopsy
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 December 2017
- Peppol
- Active · Active since 18 Jun 2025
- Activities · NACE
Activiteiten van medisch specialisten
Activiteiten op het gebied van psychologie
Activiteiten op het vlak van geestelijke gezondheidszorg, m.u.v. psychiatrische ziekenhuizen en verzorgingstehuizen